

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 AND 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934

For the Month of December 2013

File No. 000-54598

**Stellar Biotechnologies Inc.**

(Name of Registrant)

**332 E. Scott Street, Port Hueneme, CA 93041**

(Address of principal executive offices)

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
FORM 20-F  FORM 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 6-K to be signed on its behalf by the undersigned, thereunto duly authorized.

Stellar Biotechnologies Inc.  
(Registrant)

Dated: December 3, 2013

By: /s/ "Kathi Niffenegger"  
Kathi Niffenegger  
Chief Financial Officer

**Exhibits:**

**99.1 News Release dated December 3, 2013**

## Stellar Biotechnologies to Host Corporate Update Conference Call and Webcast on December 11

*Management to discuss recent achievements and future catalysts for growth*

PORT HUENEME, CA, (December 3, 2013) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), will host a general corporate update and conference call virtual presentation webcast at 11:00 AM ET (8:00 AM PT) on December 11, 2013.

The Company will review the significant milestones achieved in 2013 including its acquisition of exclusive rights to an innovative KLH-based immunotherapy technology to treat Clostridium difficile infection ("C. diff"), as well as recent manufacturing and R&D progress. In addition, Stellar's management will discuss the Company's plans for expansion involving potential catalysts in R&D, manufacturing and business development.

### Telecast and Webcast Information:

**Date:** Wednesday, December 11, 2013

**Time:** 8:00 AM PT/ 11:00 AM ET

**US Dial-in (Toll-free):** 1-877-941-1427

**International Dial-in:** 1-480-629-9664

**Conference Call ID:** 4653815

**Webcast Link:** <http://public.viavid.com/index.php?id=107091>

For the live and archived webcast, please visit the investor presentation section on Stellar Biotechnologies' website at: [www.stellarbiotech.com](http://www.stellarbiotech.com)

A replay of the call will be available through December 25, 2013. To access the replay, please call 1-877-870-5176 if calling from North America and 1-858-384-5517 if calling from outside the U.S. and Canada. The replay passcode is 4653815, for additional information please visit the investor section of the company website at [www.stellarbiotech.com](http://www.stellarbiotech.com).

### About Stellar Biotechnologies, Inc.

**Stellar Biotechnologies, Inc. (TSX-V: KLH) (US OTCQB: SBOTF)** is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

To receive regular updates, enter email at <http://stellarbiotechnologies.com/contact/>  
Visit [www.StellarBiotech.com](http://www.StellarBiotech.com) and the KLH knowledge base [www.KLHSite.com](http://www.KLHSite.com).

### Company Contacts:

Frank Oakes

President and CEO

Phone +1 (805) 488-2800

[investorrelations@stellarbiotech.com](mailto:investorrelations@stellarbiotech.com)

Mark A. McPartland

Vice President of Corporate Development and Communications

Phone: +1 (805) 488-2800 ext. 103

[markmcp@stellarbiotech.com](mailto:markmcp@stellarbiotech.com)

[www.stellarbiotech.com](http://www.stellarbiotech.com)

### Forward Looking Statements

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.

